639 原发性晚期或复发性子宫内膜癌患者免疫相关不良事件的管理:ENGOT-EN6-NSGO/GOG-3031/RUBY试验中多司他(dostarlimab)联合化疗与单纯化疗的比较

Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt
{"title":"639 原发性晚期或复发性子宫内膜癌患者免疫相关不良事件的管理:ENGOT-EN6-NSGO/GOG-3031/RUBY试验中多司他(dostarlimab)联合化疗与单纯化疗的比较","authors":"Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt","doi":"10.1136/ijgc-2024-esgo.34","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"27 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial\",\"authors\":\"Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt\",\"doi\":\"10.1136/ijgc-2024-esgo.34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"27 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信